Cargando…

Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma

Detalles Bibliográficos
Autores principales:	Jain, Preetesh, Nomie, Krystle, Kotlov, Nikita, Segodin, VitaIy, Hill, Holly, Ok, Chi Young, Fetooh, Ahmed, Kanagal-Shamanna, Rashmi, Vega, Francisco, Bagaev, Alexander, Fowler, Nathan, Flowers, Christopher R., Wang, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567800/ https://www.ncbi.nlm.nih.gov/pubmed/37821434 http://dx.doi.org/10.1038/s41408-023-00927-2

Ejemplares similares

Blastoid and Pleomorphic Mantle Cell Lymphoma Demonstrate Distinct Clinicopathologic and Genetic Features
por: Khanlari, Mahsa, et al.
Publicado: (2023)

BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner
por: Munoz, Javier L., et al.
Publicado: (2022)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

EZH2 expression is associated with inferior overall survival in mantle cell lymphoma
por: Martinez-Baquero, Diana, et al.
Publicado: (2021)

Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma
por: Zhang, Shaojun, et al.
Publicado: (2021)

Smoldering mantle cell lymphoma
por: Ye, Haige, et al.
Publicado: (2017)

Gene mutations and actionable genetic lesions in mantle cell lymphoma
por: Ahmed, Makhdum, et al.
Publicado: (2016)

The B cell receptor signaling pathway in mantle cell lymphoma
por: Merolle, Maria I., et al.
Publicado: (2018)

NF-κB signaling and its relevance to the treatment of mantle cell lymphoma
por: Balaji, Swathi, et al.
Publicado: (2018)

Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
por: Burkart, Madelyn, et al.
Publicado: (2022)

Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma
por: Hill, Holly A., et al.
Publicado: (2023)

Spontaneous regression of mantle cell lymphoma: a report of four cases
por: Ye, Haige, et al.
Publicado: (2018)

Biomarkers in Acute Myeloid Leukemia: Leveraging Next Generation Sequencing Data for Optimal Therapeutic Strategies
por: El Achi, Hanadi, et al.
Publicado: (2021)

Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy
por: Ye, Haige, et al.
Publicado: (2018)

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
por: Qi, Jialei, et al.
Publicado: (2023)

NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells
por: Li, Yangguang, et al.
Publicado: (2017)

Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma
por: Zhang, Jing, et al.
Publicado: (2022)

Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2023)

Advances in the assessment of minimal residual disease in mantle cell lymphoma
por: Jung, Dayoung, et al.
Publicado: (2020)

The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma
por: Huang, Shengjian, et al.
Publicado: (2018)

Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma
por: Liu, Zhuojun, et al.
Publicado: (2021)

Nucleophosmin 1 Mutations in Acute Myeloid Leukemia
por: Zarka, Jabra, et al.
Publicado: (2020)

Depletion of the upper mantle by convergent tectonics in the Early Earth
por: Perchuk, A. L., et al.
Publicado: (2021)

Smudge cells in CD200(+), TP53 mutated leukemic mantle cell lymphoma
por: Jain, Preetesh, et al.
Publicado: (2022)

The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma
por: Pal, Dhananjaya, et al.
Publicado: (2021)

Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma
por: Vann, Kendra R., et al.
Publicado: (2022)

Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
por: Kueffer, Lauren E., et al.
Publicado: (2021)

Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab
por: Jain, Punit, et al.
Publicado: (2016)

Consolidative opacity in a patient with acute leukemia
por: Banala, Chaitra, et al.
Publicado: (2022)

Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK
por: Wang, Xianhuo, et al.
Publicado: (2021)

Depletion of potassium and sodium in mantles of Mars, Moon and Vesta by core formation
por: Steenstra, E. S., et al.
Publicado: (2018)

Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma
por: Thieme, Elana, et al.
Publicado: (2022)

Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression
por: Han, Guangchun, et al.
Publicado: (2022)

Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
por: Beitinjaneh, Amer, et al.
Publicado: (2022)

No significant regulation of bicoid mRNA by Pumilio or Nanos in the early Drosophila embryo
por: Wharton, Tammy H., et al.
Publicado: (2018)

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
por: Joseph, Raji E, et al.
Publicado: (2020)

The Tharsis mantle source of depleted shergottites revealed by 90 million impact craters
por: Lagain, A., et al.
Publicado: (2021)

P1207: SERIAL SINGLE-CELL PROFILING OF MANTLE CELL LYMPHOMA REVEALS FUNCTIONAL AND MOLECULAR CORRELATES OF RESISTANCE TO BTK INHIBITOR-INCLUSIVE TRIPLET THERAPY
por: Debaize, Lydie, et al.
Publicado: (2023)

Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations
por: Che, Yuxuan, et al.
Publicado: (2023)

Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study
por: Hess, Lisa M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vhld2uhm8f5mm27vn1v12kr9du